142 related articles for article (PubMed ID: 3012375)
1. Action of AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonylmet hox y coumarin) on human platelets in vitro.
Prosdocimi M; Zatta A; Gorio A; Zanetti A; Dejana E
Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):305-10. PubMed ID: 3012375
[TBL] [Abstract][Full Text] [Related]
2. The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxy- carbonylmethoxycoumarin) on washed human platelet aggregation induced by platelet activating factor (PAF) and epinephrine.
Zanetti A; Zatta A; Prosdocimi M; Dejana E
Eur J Pharmacol; 1986 Aug; 128(1-2):119-27. PubMed ID: 2944757
[TBL] [Abstract][Full Text] [Related]
3. AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonyl-meth oxy coumarin) inhibits the release of arachidonic acid in human platelets stimulated by thrombin.
Porcellati S; Costantini V; Prosdocimi M; Pistolesi R; Porrovecchio P; Nenci GG; Goracci G
Thromb Res; 1987 Jul; 47(1):15-24. PubMed ID: 3116710
[TBL] [Abstract][Full Text] [Related]
4. Effects of 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy carboxyl methoxy coumarin (AD6) on aggregation, arachidonic acid metabolism and thromboxane B2 formation in human platelets.
Galli C; Agradi E; Petroni A; Socini A
Pharmacol Res Commun; 1980 Apr; 12(4):329-37. PubMed ID: 7393988
[No Abstract] [Full Text] [Related]
5. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery.
Prosdocimi M; Finesso M; Tessari F; Gorio A; Languino LR; de Gaetano G; Dejana E
Thromb Res; 1985 Aug; 39(4):399-409. PubMed ID: 3840290
[TBL] [Abstract][Full Text] [Related]
6. Molecular aspects of cloricromene (AD6) distribution in human platelets and its pharmacological effects.
Travagli RA; Zatta A; Banzatto N; Finesso M; Mariot R; Tessari F; Prosdocimi M
Thromb Res; 1989 May; 54(4):327-38. PubMed ID: 2763271
[TBL] [Abstract][Full Text] [Related]
7. At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation.
Zatta A; Zanetti A; Dejana E; Prosdocimi M
Agents Actions; 1987 Oct; 22(1-2):151-8. PubMed ID: 2961218
[TBL] [Abstract][Full Text] [Related]
8. Effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonylme tho xy coumarin) on cyclic nucleotide phosphodiesterases in human platelets.
Hakim G; Fiorentini D; Falasca A; Prosdocimi M; Rossi CA
Experientia; 1988 Mar; 44(3):226-8. PubMed ID: 2832208
[TBL] [Abstract][Full Text] [Related]
9. Lack of antiplatelet activity of the new coumarin derivative 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy- carboxylmethoxycoumarin under in vivo conditions in man.
Luzzatto G; Fabris F; Dal Bo Zanon R; Girolami A
Arzneimittelforschung; 1986 Jun; 36(6):972-3. PubMed ID: 2943294
[TBL] [Abstract][Full Text] [Related]
10. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
11. The coumarin derivative AD6 inhibits the release of arachidonic acid by interfering with phospholipase A2 activity in human platelets stimulated with thrombin.
Porcellati S; Costantini V; Prosdocimi M; Stasi M; Pistolesi R; Nenci GG; Goracci G
Agents Actions; 1990 Mar; 29(3-4):364-73. PubMed ID: 2111085
[TBL] [Abstract][Full Text] [Related]
12. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
13. Effects of the coumarin derivative AD6 on platelet aggregation, platelet vessel wall interactions and 6 keto PGF1 alpha production in perfused aortas, in experimentally hypercholesterolaemic rabbits.
Socini A; Petroni A; Colli S; Colombo C; Galli C
Pharmacol Res Commun; 1982 Mar; 14(3):189-97. PubMed ID: 7048340
[No Abstract] [Full Text] [Related]
14. Effect of labetalol on human platelet function.
Anfossi G; Trovati M; Lanzio M; Mularoni E; Massucco P; Emanuelli G
Clin Exp Pharmacol Physiol; 1988 Jun; 15(6):437-48. PubMed ID: 2856060
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
de Clerck F; David JL; Janssen PA
Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human platelet function in vitro and ex vivo by acetaminophen.
Lages B; Weiss HJ
Thromb Res; 1989 Mar; 53(6):603-13. PubMed ID: 2499947
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of p-chlorobiphenyl on the inhibition of platelet aggregation.
Ko FN; Yeh LJ; Liang HC; Kuo SC; Teng CM
J Pharm Pharmacol; 1996 Apr; 48(4):395-400. PubMed ID: 8794990
[TBL] [Abstract][Full Text] [Related]
18. Observations on the effects of some antiaggregating drugs on platelet specific protein discharge after a very weak stimulus.
Weber G; Bianciardi G; Toti P; Massari P; Orlando P
Pharmacol Res Commun; 1985 Feb; 17(2):129-35. PubMed ID: 3158006
[TBL] [Abstract][Full Text] [Related]
19. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation.
Nichols AB; Owen J; Grossman BA; Marcella JJ; Fleisher LN; Lee MM
Circulation; 1984 Nov; 70(5):843-50. PubMed ID: 6237807
[TBL] [Abstract][Full Text] [Related]
20. A new congenital defect of platelet secretion: impaired responsiveness of the platelets to cytoplasmic free calcium.
Hardisty RM; Machin SJ; Nokes TJ; Rink TJ; Smith SW
Br J Haematol; 1983 Apr; 53(4):543-57. PubMed ID: 6830700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
